Xenikos Announces IND Clearance by the FDA for a Pivotal Phase 3 Trial Using T-Guard(R) for Treating Steroid-refractory Acute GVHD

Media coverage

• Title	Xenikos Announces IND Clearance by the FDA for a Pivotal Phase 3 Trial Using T-Guard(R) for Treating Steroid-refractory Acute GVHD
  Media name/outlet	Plus Company Updates (PCU)
  Country/Territory	United States
  Date	12/06/19
  Persons	John Levine